Market Overview

Imperial Capital Lowers PT on Amylin Pharmaceuticals to $7.50

Imperial Capital has lowered the price target on Amylin Pharmaceuticals (NASDAQ: AMLN) from $10 to $7.50 and maintains its Underperform rating.

Posted-In: imperial capitalPrice Target Pre-Market Outlook Analyst Ratings

 

Related Articles (AMLN)

Around the Web, We're Loving...

Get Benzinga's Newsletters